ABC transporter proteins couple the energy of ATP binding and hydrolysis to substrate transport across a membrane. In humans, clinical studies have implicated mutations in 19 of the 48 known ABC transporters in diseases such as cystic fibrosis and adrenoleukodystrophy. Although divergent in sequence space, the overall topology of these proteins, consisting of two transmembrane domains and two ATP-binding cassettes, is likely to be conserved across diverse organisms. We examine known intra-transporter domain interfaces using crystallographic structures of isolated and complexed domains in ABC transporter proteins and find that the nucleotide binding domain interfaces are better conserved than interfaces at the transmembrane domains. We then apply this analysis to identify known disease-associated point and deletion mutants for which disruption of domain-domain interfaces might indicate the mechanism of disease. Finally, we suggest a possible interaction site based on conservation of sequence and disease-association of point mutants.
Introduction
ATP-binding cassette (ABC) transporters are membrane-spanning proteins that transport a wide variety of small molecule substrates and ions across cell membranes. Examples include the multidrug transporter P-gp, associated with drug resistance phenotypes in cancer therapy [1] , and the cystic fibrosis transmembrane conductance regulator (CFTR) that transports chloride ions [2] . In Escherischia coli, the vitamin B12 transporter BtuCD is also an ABC transporter [3] , further underscoring the diversity of molecules transported by these proteins.
In humans, the ABC transporters are divided into seven families, labeled ABCA through ABCG. There are half transporters, such as the breast cancer resistance protein BCRP (ABCG2), that consist of one nucleotide-binding domain (NBD) and one transmembrane domain (TMD), and whole transporters, such as the sulfonylurea transporter (ABCC8), that consist of two NBDs and two TMDs [4] . In bacteria and archaea, the NBD and TMD domains are frequently separate genes and the corresponding proteins must associate for mutations, we examined known domain interactions in high-resolution crystal structures and used our analysis to suggest possible interface-related mechanisms of human disease. We comprehensively map known disease mutations onto putative nucleotide binding domain interface sites in human ABC transporters. The putative interfacial residues identified in this study can be used to focus efforts in the biochemical identification of functionally important residues.
Methods

Sequence collection and generation of multiple sequence alignments
There are 35 structures of ABC transporter proteins in the PDB as of July, 2006. We selected six for study based on the following considerations: diversity of organism representation, diversity of transporter family representation, structural resolution, and completeness of structure as defined by the number of domains crystallized. We selected four structures with definable interfaces. Two are complete ABC transporters with two NBDs and two TMDs: the structure of the vitamin B12 transporter from E. coli [3] and the MsbA lipid A exporter from Salmonella typhimurium [13] . Two structures are NBD dimers, one from Methanococcus jannaschii, and the other from E. coli [6, 7] . The final two structures are human transporter NBD monomers [14, 15] .
Sequences homologous to each of the proteins in Table 1 were culled by iteratively searching the Uniprot database [16] using the build_profile module of MODELLER [17] with a threshold e-value of 0.01. Build_profile is an iterative database searching method that uses dynamic programming for aligning profiles against sequences and an empirical definition of statistical significance based on the scores collected during the scan of the database [18] . Such automated alignments were also generated for each of the 76 nucleotide binding domains in the 48 human transporters. We used diverse, superfamily-level multiple sequence alignments to examine patterns of conservation across the whole family of ABC transporters rather than dividing the transporters by subfamily. S. typhimurium 4.20 Complete structure of the lipid A exporter MsbA, which is homologous to human multidrug resistance transporters [13] The 
Evolutionary conservation: sequence weights and residue position entropies
We use Shannon entropy to measure the evolutionary conservation at each position (column) in our multiple sequence alignments [19] . Henikoff weighting [20] was used to ensure that entropy calculations were not skewed by large numbers of highly similar sequences which are common in alignments of ABC transporters and which can be a problem with large automatically generated alignments in general. In Henikoff weighting, each column is given an initial weight of 1, which is divided equally between distinct amino acid residues in the column. Within a column, the weight for each amino acid residue is divided equally by the number of times it occurs. Finally, the weight of any given sequence is the sum of the weights of all of the amino acid residues in the sequence. A Shannon entropy:
was calculated for each column where P aa is defined as:
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where
and w(i) is the sequence weight and n aa is the number of amino acid residues of a particular type seen in the column. Because of the minus sign in Equation (1), lower numbers indicate greater evolutionary conservation. A MATLAB implementation of Henikoff weighting and the sequence weighting-based Shannon entropy calculation are available on request.
Interface definition
Domain interfaces were defined according to PiBase, a database of domain interactions from x-ray crystal structures in PDB that uses a 5.5Å cutoff for heavy atom interatomic distances to define residues at an interface [21] . The functional unit of ABC transporters is two transmembrane domains (TMD) complexed with two nucleotide-binding domains (NBD) [3, 13, 5] . For the complete ABC transporter structure BtuCD, we define three interfaces: NBD/TMD, NBD/NBD and TMD/TMD. For the dimeric structures we define only the NBD/NBD interfaces. The structure of each domain was aligned to the BtuCD structure (for TMD/NBD interactions) and the Mj0796 structure (for NBD/NBD interactions) with the salign routine in MODELLER [17] . All residues that aligned to interface residues in BtuCD or Mj0796 were predicted to also be interface residues.
Homology transfer annotations
We used the multiple sequence alignments to predict the locations of interface amino acid residues in each of the human ABC transporter NBDs. We assume that if a residue aligns to a known interface residue in the Mj0796 structure (for NBD/NBD alignments) or the BtuCD structure (for NBD/TMD alignments) that it is also at an interface in homologous family members. Residues that aligned to defined interface residues (Interface definition) were examined for disease associations as annotated in the VARIANT records of the Uniprot database [16] .
Surface conservation
We used the molecular graphics visualization program Chimera [22] to identify sites of putative binding interactions that have not yet been functionally characterized, by locating surface regions of medium to high conservation (excluding defined interface sites). Medium conservation is defined as no greater than half of the highest column entropy found in a given alignment ( Figure 2B ). [15] . Interface residues were defined using homology transfer annotation based on the structure of an NBD dimer from M. jannaschii (PDB ID: 1L2T) [6] and are shown in gold. Residues with known cystic fibrosisassociations at the NBD/NBD interface are shown in black ( Table  2 ). An N-terminal helix in the CFTR structure is hidden to show the complete interface as defined by the 1L2T structure.
(B). The exposed, non-NBD surface of the 1L2T structure. Residue positions in yellow have entropies of no more than 2.1 bits. Residue positions in black are associated with cystic fibrosis (CFTR), adrenoleukodystrophy (ALD) and high-density lipoprotein deficiency type 2 (ABCA1).
Results
Differential conservation of interfaces in ABC transporters
We examined evolutionary conservation at the amino acid residue level for three different interfaces in ABC transporter structures (Interface definition). Figure 3 . Evolutionary conservation at binding and interface sites in six ABC transporter structures. The ATP binding site, which forms part of the interface between the nucleotide binding domains (NBDs) has the lowest entropy due to highly conserved residues in the Walker A, B and 'signature' motifs. The NBD/NBD interface is well conserved even when the ATP-binding residues are removed from consideration (NBD/noATP). The TMD interfaces, both with the cognate NBD and the cognate TMD (only definable for 1Z2R and 1L7V) are not highly conserved.
We were only able to define the TMD/TMD interface for the two complete structures, 1Z2R and 1L7V. We found that the NBD/NBD interface was consistently more conserved than either the NBD/TMD and TMD/TMD interfaces (Figure 3 , Discussion).
Disease associated mutations at ABC transporter interfaces
We found a total of 68 disease-associated positions at PiBase-defined interfaces in 10 transporters (Table 2, Figure 2A ). Of these positions, 65 were single residue mutations and three were deletions. Thirty-eight mutations were at the NBD/NBD interface and 30 at the NBD/TMD interface. We also found conserved surface residues that included two positions associated with disease in several ABC transporters. These residues correspond to the 1L2T residues 1, 2, 31, 60, 164, and 213. There are 587 total known disease mutations in the 10 transporters, of which 504 are found in ABCC7, ABCD1 or ABCA4 [16] . Table 2 . Disease associated mutations at putative ABC transporter interfaces. Human protein residues that aligned with the NBD/NBD or NBD/TMD interface were examined for disease association using Uniprot [16] . The two interfaces overlap by two residues. 
Discussion
We have comprehensively mapped known disease-associated mutations to putative interfaces and found that 68 disease-associated positions in 10 transporters fall at putative interfaces. This indicates that a majority of diseaseassociated ABC transporters (10/17) have mutations at interface regions. Single residue point mutations were the most common and accounted for 65 of the disease-associated positions; the other three were single residue deletions. Thirty-eight mutations were at the NBD/NBD interface and 30 at the NBD/TMD interface. We hypothesize that many disease-association mutations involving ABC transporters may be due to disruption of domain-domain binding interactions.
Proper function of ABC transporters involves cycles of substrate binding and release which are currently thought to be governed by an 'ATP switch'-type mechanism with ATP binding and hydrolysis causing formation and dissociation of an NBD/NBD dimer. The switch, between open and closed dimer states, causes conformational changes in the TMDs that enable substrate transport [5] . While large conformational changes have been seen in mammalian ABC transporters using electron microscopy [23, 24] , the specific residue interactions at both the NBD/NBD interface and the TMD/NBD interface that are involved in these interactions in human transporters is lacking.
As noted earlier, interface mutations can disrupt ABC transporter domain interactions in several ways: by interfering with ATP binding or hydrolysis, by destabilizing or preventing proper folding and association of the domains, or by interfering with allosteric communication between domains that is suggested by the large conformational changes seen during the transport cycle. Defining residues at these interfaces is useful to experimentalists interested in examining specific residue interactions that stabilize or abrogate interface interactions. For example, in CFTR, a hypothesized hydrogen bond between R555 in NBD1 and T1246 in NBD2 stabilizes the open, chloride-transporting state of the protein [27] . The high conservation of the NBD/NBD interface at the superfamily level suggests that there are likely additional residue interactions that stabilize dimer formation and facilitate transport.
The relative lack of conservation at the TMD/NBD interface and the large number of disease-associated mutations at this interface ( Table 2 ) might indicate that NBD/TMD mutations might lead to defects in folding and maturation rather than directly affecting the function of a properly processed, intact transporter. The ΔF508 mutant falls at the TMD/NBD interface and leads to an immature protein that is tagged for degradation and does not localize properly to the cell membrane [2] . A recent study showed that mutating the analogous residue in Pglycoprotein (MDR1), Y409, also led to an immature form of the protein with an altered NBD/NBD interface. This observation indicates a misfolded protein with improper or incomplete domain associations [25] . Another predicted TMD/NBD interface mutant, R1435Q mutant in ABCC8, could not form functional KATP channels and showed 10-fold reduced expression compared to wild-type ABCC8. Either protein instability or defective transport to the cell membrane could cause this phenotype [26] . Alternatively, the lack of conservation at this interface might suggest TMD/NBD interactions are subfamily specific, in contrast to the overall high conservation of residues at the NBD/NBD interface.
Given the 30 disease mutants at this interface, the lack of conservation at the NBD/TMD interface does not indicate that this region is unimportant for ABC transporter function. However, it suggests that instead of a larger conserved interaction footprint as seen in the NBD/NBD interface, perhaps a small number of conserved residues form the necessary contacts for communication between the domains. In the TMD of BtuCD, the A221 in the L2-loop is one of only three moderate to highly conserved residues in the TMD. In MsbA, the residues G122 and E208 are well conserved, and contribute to the TMD/NBD interface.
We also suggest a possible interaction site distinct from those observed in the crystallographic structures based on conserved surface residues and diseaseassociation in human ABC transporters ( Figure 2B ). Surface residues not at defined interfaces are generally not well conserved (Appendix Figure A1 ) in our analysis. However, a moderate to highly conserved region on the surface of the 1L2T structure includes the aligned human mutations: D1099Y, in ABCA1 associated with high density lipoprotein deficiency type 2, D614G in CFTR associated with cystic fibrosis and T668I in ABCD1 associated with adrenoleukodystrophy.
Observing three different transporters with disease-associated mutations at the same solvent-exposed position suggests that this position is conserved for a functional reason. If the residues indeed form part of an interaction site with an unknown partner, that partner might also be conserved in multiple transporters. Alternatively, these residues could indicate a region that stabilizes oligomerization of complete ABC transporters. This example also demonstrates the utility of homology transfer annotation for locating functionally important residues.
There is little experimental data available defining the specific effect of disease-associated mutations on ABC transporters. A recent review noted that the majority of CFTR mutants have not been experimentally characterized [2] .
The difficulty of working with these large membrane proteins underscores the need for computational analysis that provides hypotheses for the mechanism of domain interactions in ABC transporters that can be verified experimentally. We used this analysis to prioritize residues selected to experimentally probe domain interactions in the human multidrug ABC transporter P-gp. We will apply our method to new ABC transporter structures as they become available, and we intend to explore using other measures of residue conservation, including determining site-specific mutation rates and locating coevolving residues, in the future [28, 29] .
